SCHEMBL31577583

SCHEMBL31577583

NNCc1ccc(C(N)=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.53
PLA2G2A P14555 1/20 0.53
EPHX2 P34913 1/20 0.53
NR1H4 Q96RI1 1/20 0.53
PARP10 Q53GL7 4/20 0.50
IDO1 P14902 1/20 0.48
VNN1 O95497 1/20 0.47
KDM1A O60341 1/20 0.47
MAOA P21397 1/20 0.47
CA2 P00918 2/20 0.47
CYP3A4 P08684 2/20 0.46
MAPT P10636 2/20 0.46
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
OPRK1 P41145 1/20 0.46
CYP17A1 P05093 1/20 0.46
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.45
PARP15 Q460N3 1/20 0.45
PARP14 Q460N5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1402894 0.83 KMT2A (0.60) EPHX2NR1H4IDO1CA2CYP3A4
SCHEMBL10561443 0.83 MPO (0.59) IDO1CA2CYP3A4MAPTKMT2A
SCHEMBL10209044 0.81 PLA2G10 (0.52) PLA2G10PLA2G2AEPHX2NR1H4PARP10
SCHEMBL3882642 0.81 PLA2G10 (0.57) PLA2G10PLA2G2AEPHX2NR1H4PARP10
SCHEMBL19091139 0.81 PLA2G10 (0.52) PLA2G10PLA2G2AEPHX2NR1H4PARP10
SCHEMBL16162038 0.79 EPHX2 (0.58) PLA2G10PLA2G2AEPHX2NR1H4PARP10
SCHEMBL18235891 0.78 EPHX2 (0.53) PLA2G10PLA2G2AEPHX2NR1H4PARP10
SCHEMBL5929617 0.78 KMT2A (0.70) PLA2G10PLA2G2AEPHX2NR1H4PARP10
SCHEMBL11869981 0.78 ALDH1A1 (0.60) PLA2G10PLA2G2AEPHX2NR1H4PARP10
SCHEMBL3306120 0.78 ADH1B (0.53) PLA2G10PLA2G2AEPHX2NR1H4PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163488-A1 CONJUGATION METHOD INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRIMMED N-GLYCAN BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) 2025-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163488-A1 CONJUGATION METHOD INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRIMMED N-GLYCAN ENGASE, B3GAT3, FCGR2A PLA2G10 2200/4885PLA2G2A 1409/4885EPHX2 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.